- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03687541
In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital (HEMO-CIH)
Anticoagulant and antiplatelet treatments have well defined indactions, with a clearly proved benefit, respectivly for prevention of arterial and venous emblism and for prevention of athermo-related arterial thrombosis.
Bleeding risk represents the main adverse effect of these antithrombotic medications. Then benefit-risk ratio is sometimes difficult to evaluate, especially for elderly patients prone to fall (incidence of falls estimated to 30% per year for patients over 65), exposed on the one hand to thromboembolic risk and on the other hand to bleeding risk.
Associations between falls and antithrombotic-related bleeding risk had already been evaluated in several studies :
- Concerning anticoagulant treatments in patients at high risk of falls, retrospective studies shown a overrated risk of intracranial hemorrhage and mortality, but those results remain discordant wtih 3 major prospective studies on larger populations.
- Concerning antiplatelet treatments in patients at high risk of falls, majority of retrospective studies reported an overrated risk of major bleeding, intracranial bleeding and mortality, but datas remain fewer than for anticoagulant and results are as well discordant with prospective studies.
- No difference of morbi-mortality is clearly estalblished depending of antithrombotic treatment class (anticoagulant versus antiplatelet), however there is a cumulative risk in case of association of both anticoagulant and antiplatelet.
- Main factors associated with fall-related bleeding for patients on anticoagulant include age, female sex, anemia, chronic kidney disease, dementia and polymedication.
Thus, the purpose of this study is to specify whether occurrence of falls justify to reconsider prescription of antithrombotic treatments in patients having an indication of antiplatelet or anticoagulant therapy.
Visão geral do estudo
Status
Condições
Descrição detalhada
Retrospective, descriptive and non-interventional study over a period of 12 months (from 01/01/2017 to 31/12/2017), from unwanted events database of Rennes University Hospital.
Patients meeting criterias receive an information mail. Without opposition over a period of 3 weeks, datas will be treated, focusing on the event and its consequencies until hospital outing.
Baseline characteristics :
- Demographic datas : age, sex
- Antithrombotic treatement, treatment class and molecule
- Last INR dosage before the fall for patients of vitamin K antagonists
- Antithrombotic treatment indication : supra-ventricular arythmia, heart valve mecanical prothesis, severe left ventricle hypokinesia, venous thromboembolism, anti-phospholipid syndrome, myeloproliferative disorder, atheroma (in primary or secondary prevention)
- Comorbidities : history of bleeding (including hemorrhagic stroke), haemostasis disorder, thrombocytopenia, anemia, chronic kidney disease, chronic liver disease, alcohol abuse, ischemic stroke or transient ischemic stroke, cognitive disoreder, active neoplasm, HAS-BLED score, HEMORRHAGE score
- Other undergoing treatments : total number of medications, antihypertensive treatment, psychotropic treatment, non-steroid anti-inflamatory treatment
Description of fall-related bleeding events rate (until hospital outing) according to the severity :
- Any severity bleedings
- Major bleedings (hemorrhagic shock, deglobulisation, red blood cells transfusion required, vital or functional-threatening bleeding spot, uncontrolled hemorrhage requiring specialized haemostatic intervention)
- Intracranial bleeding
- Fatal bleeding
Modification of the antithrombotic prescription in the aftermath of the fall :
- Discontinuation or suspension of antithrombotic treatment
Sub-group analysis for each previous item, according to undergoing antithrombotic treatment at the moment of the fall :
- Curative-dose anticoagulant in monotherapy
- Preventive-dose anticoagulant in monotherapy
- Antiplatelet in monotherapy
- Curative-dose anticoagulant and antiplatelet in association
- Preventive-dose anticoagulant and antiplatelet in association
- No antithrombotic treatement
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Rennes, França, 35
- Centre Hospitalier Universitaire de Rennes
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Hospitalized patients in internal medicine unit in Rennes University Hospital, from 1/01/2017 to 31/12/2017
- Age over 18
- In-hospital fall reported in unwanted event database
- Separated inclusion for each fall in the same patient
Exclusion Criteria:
- Adults on legal protection (safeguarding justice, trusteeship, guardianship) or deprived of liberty
- Patient opposed to inculsion
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Any-severity fall-related hemorrhagic events rate
Prazo: The inclusion day
|
All reported hemorrhagic events after a fall
|
The inclusion day
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Patrick Jego, MD PhD, Rennes University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 35RC18_3089_HEMO-CIH
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em In-hospital Falls
-
Centre Hospitalier Universitaire, AmiensConcluído
-
Boston Medical CenterConcluídoReadmissão, HospitalEstados Unidos
-
National University Health System, SingaporeNational University of SingaporeConcluído
-
University of PennsylvaniaConcluídoUtilização | Laboratório, Hospital
-
Aydin Adnan Menderes UniversityConcluído
-
University of SouthamptonUniversity of Leeds; Newcastle-upon-Tyne Hospitals NHS Trust; National Institute... e outros colaboradoresAinda não está recrutandoDescondicionamento associado ao hospital
-
Hospital Italiano de Buenos AiresConcluídoCompromissos e Agendamentos | Ambulatórios, HospitalArgentina
-
Zealand University HospitalRegion Zealand; Roskilde Municipality; Køge Municipality; Stevns Municipality; Solrød... e outros colaboradoresConcluídoPlanejamento de alta | Readmissão, HospitalDinamarca
-
Medical University InnsbruckConcluídoPessoal, Hospital | Contaminação do equipamento | Environmental MicrobiologyÁustria